Komori
Statutory disclosure document4884Kringle Pharma,Inc.Pharmaceuticals

Completion of PMDA Review of the Clinical Trial Notification for the Additional Phase III Trial of HGF (Hepatocyte Growth Factor) in Acute Spinal Cord Injury

PMDA has completed its review of the clinical trial notification for the additional Phase III trial of an HGF formulation in acute spinal cord injury. The trial is scheduled to begin after approval by the IRBs at each site.

Worth reading
56In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
10
Target number of subjects
Wording
Conditional
How definitive the wording is.

No category-specific facts could be extracted from this document.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

PMDA has completed its prescribed review of the clinical trial notification that had been submitted to PMDA.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Completion of PMDA Review of the Clinical Trial Notification for the Additional Phase III Trial of HGF (Hepatocyte Growth Factor) in Acute Spinal Cord Injury | Kringle Pharma,Inc. (4884) timely disclosure | Komori